Revised Schedule M Guidelines: Drug Recall and Ensuring Pharma Quality

Dr. Reddy highlights that this initiative will empower companies to collect, process, and report adverse drug reactions (ADRs) promptly.

330
Schedule-M
Schedule-M

Last Updated on December 31, 2023 by The Health Master

Revised Schedule M

In a significant move towards ensuring drug safety and quality, the proposed Revised Schedule M guidelines are set to introduce a comprehensive system for prompt and effective drug recall.

Dr. S Eswara Reddy, Joint Drugs Controller at the Central Drugs Standard Control Organisation (CDSCO), emphasizes the pivotal provisions that will revolutionize the pharmaceutical landscape.

Current Scenario: Gaps in Drug Recall Procedures

Currently, the absence of a provision to inform the licensing authority about drug recalls poses a substantial challenge.

The proposed guidelines aim to bridge this gap by introducing provisions for reporting product deterioration, faulty manufacturing, and serious quality issues to the Licensing Authority (LA) in a timely manner.

Pharmacovigilance Cells: A Prerequisite for WHO-GMP Standards

Under the Revised Schedule M guidelines, pharmaceutical companies are mandated to establish pharmacovigilance (PV) cells to meet the stringent standards of the World Health Organisation-Good Manufacturing Practices (WHO-GMP).

Dr. Reddy highlights that this initiative will empower companies to collect, process, and report adverse drug reactions (ADRs) promptly.

Key Requirements of Schedule M: Ensuring Pharmaceutical Excellence

Schedule M lays down crucial requirements for pharmaceutical manufacturing plants, encompassing aspects such as maintenance, manufacturing, control and safety testing, storage and transport material, written procedures and records, and traceability.

The integration of PV cells will enhance the accountability of drug-exporting companies, ensuring compliance with legal obligations related to PV.

Timeline for Implementation: Navigating the Transition

On August 2, 2023, the Union health ministry granted a 12-month window for small manufacturers and a 6-month timeframe for larger units to obtain WHO-GMP certification.

The draft Schedule M, notified on October 5, 2018, underwent extensive discussions with drug manufacturers associations and stakeholders.

Larger companies with turnovers exceeding Rs. 250 crore are required to implement changes within 6 months, while medium and small-scale enterprises with turnovers less than Rs. 250 crore have a one-year deadline.

ADR and its Impact: A Global Healthcare Concern

Adverse Drug Reactions (ADRs) stand as a significant global health issue, contributing to morbidity and mortality.

The burden on healthcare systems includes increased therapy costs and prolonged hospitalization.

Therefore, monitoring the safety of medicines becomes imperative in addressing these challenges.

The Role of Revised Schedule M: Fostering Trust and Innovation

Designed to ensure compliance with drug standards, promote exports, encourage innovation, and build trust in the quality of pharmaceuticals, the new Schedule M heralds a transformative era for the industry.

It aligns with the government’s vision to enhance drug quality, facilitate exports, and instill confidence in both domestic and international markets.

Conclusion: A Paradigm Shift in Pharmaceutical Regulations

In conclusion, the proposed Revised Schedule M guidelines mark a paradigm shift in pharmaceutical regulations.

By addressing gaps in drug recall procedures, promoting pharmacovigilance, and setting stringent standards, these guidelines pave the way for a safer, more accountable pharmaceutical industry.

FAQs:

  1. What is Schedule M, and how does it impact pharmaceutical companies?
    Schedule M outlines requirements for pharmaceutical manufacturing, emphasizing quality, safety, and traceability. It significantly impacts companies’ compliance and accountability.
  2. How will the introduction of pharmacovigilance cells benefit pharmaceutical companies?
    Pharmacovigilance cells enable companies to monitor and report adverse drug reactions promptly, ensuring compliance with global standards.
  3. What are the deadlines for implementing the Revised Schedule M guidelines?
    Larger companies must implement changes within 6 months, while medium and small-scale enterprises have a one-year timeframe.
  4. Why is Adverse Drug Reaction (ADR) monitoring crucial in healthcare?
    ADR monitoring is essential to address increased therapy costs, prolonged hospitalization, and the overall impact on global healthcare systems.
  5. How does Revised Schedule M contribute to the government’s vision for the pharmaceutical industry?
  6. The new Schedule M contributes by enhancing drug quality, promoting exports, fostering innovation, and building trust in pharmaceutical products.

Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

YouTube Icon

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos on consumer awareness, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news